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Background: Taxanes are naturally occurring compounds which belong to a
powerful group of chemotherapeutic drugs with anticancer properties. Their
current use, clinical efficacy, and unique mechanism of action indicate their
potentiality for cancer drug discovery and development thereby promising to
reduce the high economy associated with cancer worldwide. Extensive research
has been carried out on taxanes with the aim to combat issues of drug resistance,
side effects, limited natural supply, and also to increase the therapeutic index
of these molecules. These efforts have led to the isolation of many naturally
occurring compounds belonging to this family (more than 350 different kinds),
and the synthesis of semisynthetic analogs of the naturally existing molecules
(>500), and has also led to the characterization of many (>1000) of them. A
web-based database system on clinically exploitable taxanes, providing a link
between the structure and the pharmacological property of these molecules
could help to reduce the druggability gap for these molecules.
Results: Taxane knowledge base (TaxKB, http://bioinfo.au-kbc.org.in/taxane/Taxkb/),
is an online multi-tier relational database that currently holds data on 42 parameters
of 250 natural and 503 semisynthetic analogs of taxanes. This database provides
researchers with much-needed information necessary for drug development. TaxKB
enables the user to search data on the structure, drug-likeness, and physicochemical
properties of both natural and synthetic taxanes with a “General Search” option in
addition to a “Parameter Specific Search.” It displays 2D structure and allows the user
to download the 3D structure (a PDB file) of taxanes that can be viewed with any
molecular visualization tool. The ultimate aim of TaxKB is to provide information
on Absorption, Distribution, Metabolism, and Excretion/Toxicity (ADME/T) as well
as data on bioavailability and target interaction properties of candidate anticancer
taxanes, ahead of expensive clinical trials.
Conclusion: This first web-based single-information portal will play a central role
and help researchers to move forward in taxane-based cancer drug research.
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the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Worldwide, cancer is a major public health issue accounting for approximately 8.2
million deaths and approximately 14 million new cases in 2012 that is expected
to rise to 22 million annually within the next 20 years [http://globocan.iarc.fr/
Pages/fact_sheets_cancer.aspx]. Globally vast amount of resources are being
invested for the prevention, diagnosis, and treatment of cancer. Natural com-
pounds have often offered new leads for novel molecular structures with antican-
cer activity whose synthesized analogs showed improved efficacy and toxicity
profiles [1]. The chemical diversity of these compounds has long been explored as
a rich source for the identification of unique scaffold of structures that led to
many natural product-based drugs in the market. A recent review reports that in
49 % of all cancer drugs, it was either the natural product or its derivative that
served as a starting point for the rational drug design process [2]. Among the re-
cently discovered chemotherapeutic drugs, taxanes are considered to be the most
powerful group of compounds [3]. Moreover, some of the promising results from
clinical studies have led various oncologists, researchers, and drug manufacturers
to anticipate their future consideration and development in the field of cancer [4].
National Cancer Institute discovered the first taxoid in 1960s. Schiff and his co-
workers revealed the unique pharmacological mechanisms of taxanes during 1979.
These taxanes bind to the microtubules, stabilize them, and prevent their
depolymerization thereby inhibiting cell growth [5]. Furthermore, mechanisms of their
molecular action are well characterized and include (i) cell division control 2 (cdc-2)
kinase activation, (ii) cyclin B-1 stabilization, (iii) spindle assembly checkpoint activa-
tion, (iv) apoptosis induction through B-cell lymphoma 2 (bcl-2) phosphorylation, and
(v) inhibition of cell proliferation [6]. The natural diterpene taxane, Paclitaxel and the
semisynthetic taxane, Docetaxel are deemed to be the most important among the anti-
cancer drugs. Their discovery was a breakthrough which is now considered a major
milestone in natural product-based anticancer drug discovery and development [7].
There are several key reasons why taxanes are of importance in cancer drug discovery.
These include their clinical efficacy, potential for modification and improvement,
unique mechanism of action on tubulin polymerization rather than the DNA, suitability
for combination therapy along with novel mitotic target agents being developed, as well
as selective antivascular action at nontoxic doses [8]. Furthermore, the development of
novel taxane derivatives with enhanced anticancer activity, fewer and milder side ef-
fects, and superior pharmacological properties would not only maximize the induced
benefits but also will reduce the high economic and human costs worldwide [3].
Unfortunately, these agents suffer from issues such as drug resistance, lack of specifi-
city, toxicity, poor solubility, and limited natural occurrence and availability. The issue
of drug resistance leads to a lack of response and eventual relapse of the disease in
many patients. Moreover, limited solvent availability for these compounds restricts dose
escalation and increases their toxicity which necessitates the use of premedications [9].
They are not cell-specific and do not show similar results on the microtubules when
used at different concentrations (they cause microtubule arrangement into bundles at
higher concentrations while suppressing and stabilizing microtubule dynamics without
altering the polymer mass at lower concentrations) [4]. Therefore, therapeutic index,
defined as the ratio of the TD50 (or LD50) to the ED50 as determined from quantal
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proved either by developing new drugs that target microtubules at different sites, or by
improving drug scheduling or formulations or by increasing drug specificity to increase
antitumor activity and decrease its toxicity [9]. Despite some of these disadvantages,
the utility of these compounds in cancer cannot be disregarded, given their advantages
[4]. For example, it has been found that a suitable modification of toxoids at the C10
site and replacement of phenyl group at C3 position with an alkenyl or alkyl group
leads to second-generation toxoids with one to two orders of magnitude more potency
against drug-resistant cancer cell lines [11]. Moreover, the scarcity of taxanes from nat-
ural sources also impedes their further development. Currently, commercial demands
are met through alternate semisynthetic processing of their more abundant precursors.
For example, Docetaxel is derived from 10-deacetylbacatin III, a precursor found in
more abundant Taxus (yew) species [12]. Analogs of existing drugs have also been
synthesized to increase drug targeting, pharmacokinetic profile, and drug supply [1].
To overcome the aforementioned clinical problems, the structure of taxanes has been
extensively modified to obtain new molecules with a better therapeutic index and the
ability to overcome drug resistance [13]. The enormous scope of taxanes encouraged
extensive and intensive research which led to the isolation of 350 natural taxanes from
yews, synthesis of more than 500 semisynthetic analogs, and characterization of thou-
sands of taxane molecules. The sheer volume of these discoveries motivates the need
for a web-based database system to help cancer drug developers in the war against
cancer.
Although a number of databases on chemically active natural compounds have been
published [3], there is no database devoted to the taxane family of compounds, despite
their success as antitumor agents. Examples of these existing databases on natural com-
pounds other than taxanes include SuperNatural [14], CancerResource [15], and
NPACT [2]. Hence, a comprehensive web-based database of taxanes linking their
chemical structures with known pharmacological properties is a much-needed tool in
cancer drug development. Such a tool will improve our understanding of these com-
pounds by allowing easy screening of clinically exploitable taxanes, serving quantitative
structure–activity relationships, and helping to optimize the initial lead compounds
from them. These improvements promise economic as well as scientific gains for the
pharmaceutical industry, thus enabling the creation of this platform.
Results and discussion
Taxanes
Several types of cancers including breast, ovarian, head and neck, lung, and prostate
cancer were treated by well-known anticancer drugs that belong to the taxane family.
Taxanes are biologically active diterpenes, a large and varied class of hydrocarbons with
four isoprene units that are produced from the bark of the yew tree [16]. These bio-
logically active, highly oxygenated, and esterified diterpenes’ unique structure (Fig. 1a)
consists of a tetracyclic core frame called baccatin III, with four core rings named ring
A (cyclohexene), ring B (cyclooctane), ring C (cyclohexane), and ring D (oxetane).
Important research work has been carried out to determine the structural features of
taxanes thereby revealing the biological activity of each component of the molecule.
These efforts have previously been reviewed [17]. In 1971, Wall and coworkers showed
Fig. 1 Structures of (a) Taxane (b) Paclitaxel and (c) Docetaxel [5]
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brevifolia), which was later approved for the treatment of breast cancer by the Food
and Drug Administration (FDA) in the United States. Further developments of the
compound led to the realization of a semisynthetic taxane (Docetaxel) and other taxane
analogs. The taxanes, namely, Paclitaxel and Docetaxel, routinely used in clinical prac-
tice, are known as classical taxanes [18]. The low concentration of Paclitaxel in the
original T. brevifolia and the supply crisis of Taxol or Taxotere stirred the interest to
produce these compounds by means of isolation from all other 10 geographically
isolated Taxus species including T. canadensis, T. cuspidate, T. mairei, T. baccata,
T. wallichiana, and T. yunnanensis. This effort resulted in the identification of more
than 350 taxane diterpenoids from these yew trees, expanding the diterpenoid family,
which continues to grow in size [19]. However, direct isolation from natural sources is
limited due to the slow growth of yew trees, their limited numbers in nature, as well as
very high costs, and strict national forest protection policies [20]. This has conse-
quently sparked interest in active exploration for new taxane drugs using natural tax-
anes as starting materials for synthesis and its modifications, biotransformation
employing Ginkgo, and Platycodon grandiflorus cell suspension cultures [19]. Taxus cell
culture is one example of such a renewable method for the production of this molecule.
This method has been found to be capable of producing a large amount of 4(20),
11(12)-taxadienes with C-14 oxygenated functional groups rather than with C-13
oxygenated functional groups [21]. Fig. 1 shows the structures of taxane, Paclitaxel
and Docetaxel.
TaxKB
TaxKB is an online multi-tier relational database storing drug development information
pertaining to taxanes and their analogs. It currently holds 11,000 entries with 42
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TaxKB including the well characterized ones such as Taxol, 10-Deacetylbaccatin III,
Cephalomannine, 10-Deacetyl taxol, 2′,7-bis-Acetyl taxol, 10-Deactyl taxol, 10-Deactyl
taxol B, 10-Deactyl taxol C, 10-Deactyl-7-xylosyltaxol, Cephalomannine, Taxol C,
Xylosyltaxol C, and Xylosyltaxol that show anticancer activity. It also includes a total of
503 semisynthetic taxane analogs collected from the literature. TaxKB enables users to
search specifically for individual properties of taxanes with a “General Search” option
in addition to a “Parameter Specific Search” option. It displays taxanes’ two-
dimensional (2D) as well as three-dimensional (3D) structure that can be downloaded
(as a PDB file) and viewed by any molecular visualization tool. A screenshot of TaxKB
website’s home page is shown in Fig. 2. At present, nearly 1,000 taxane molecules are
characterized and published in several journals.
The current new cancer therapy development approaches are difficult, costly, and
time-consuming, potentially taking >10 years to develop a new drug and frequently
costs more than 1 billion US dollars. In addition, the level of attrition is very high with
about 80–95 % of new drugs failing in the course of clinical trials due to lack of efficacy
or unacceptable toxicity [22]. Hence, the ultimate aim of the present TaxKB database
was to provide candidate anticancer drug taxanes’ ADME/T (Absorption, Distribution,
Metabolism, and Excretion/Toxicity) information ahead of expensive clinical trials for
predicting their bioavailability and target interacting properties. If the taxane or its frag-
ments follows the Lipinski’s Rule of five (low molecular weight ≥500, H bond donor ≥5,
H bond acceptors ≥10, log P ≥ 5) then the TaxKB information will allow for their
optimization into leads [23].
The following pieces of information were retrieved from this database suggesting its
usefulness for taxane-based cancer drug research and for mining the most appropriate
taxane for clinical development. (i) Taxanes have a minimum molecular weight ofFig. 2 Screenshot of TaxKB home page with key features and search options
Murugan et al. BioData Mining  (2015) 8:19 Page 6 of 9200 Da and the percentage of taxanes weighing between 600 and 800 Da is about 45 %.
(ii) All taxanes have a similar composition with carbon present at the highest percent-
age of about 70 %, oxygen at an average of 20 %, and hydrogen at about 10 %, while in
some compounds nitrogen is also present at low numbers (e.g. 10-Deacetyltaxine I,
10-Dideacetyltaxine II, and 9-Deacetyltaxine I). (iii) Overall, 50 % of all taxanes’
monoisotopic mass values are in the range of 600–800. (iv) About 32 % of taxanes
have a molar volume that lies in the range of 500–600 Da, within that range, 31 %
weigh between 400 and 500 Da. Information such as these provided by the database,
will be highly useful for selecting the best taxanes as drug candidates.
Methods
Data organization
MySQL Server Edition 5.1 was used for the construction of the TaxKB database. This
highly configurable and extensible user-friendly database retrieval interface was devel-
oped using PHP integrated with HTML. PubMed database searches were conducted for
English language publications using the search terms “taxane” and their derivatives.
The knowledge obtained through various resources and data on structures, drug-
likeness, and physicochemical properties of taxanes are made available on TaxKB. The
structure of taxanes is generated using structure and draw mode of ChemSketch 12.0
(http://www.acdlabs.com) and are used for their property calculation. Marvin (http://
www.chemaxon.com) was used to generate 3D structures in PDB format. For the data
of physicochemical property, the LogP, molar refractivity, molar volume, surface ten-
sion, and polarization are the included curated information. For assessing the com-
pound of interest for drug-likeness, the properties such as hydrogen bond donor’s
count, hydrogen bond acceptor’s count, rotatable bond, total polar surface area (TPSA),
and toxicity [24] are curated. For the interactive display of the current content, 2D and
3D chemical structures of 259 natural and 503 semisynthetic taxanes were either
manually created or downloaded from the PubChem database and Jmol, the java
applet-based program is used. The “three level schema architecture” followed in the
creation of the database is provided in Fig. 3. Hence, browsing TaxKB data can now be
carried out using several different available features: the “Select taxane name” feature
with a list of taxanes, the “Physicochemical properties” feature that allows searching
through 17 unique properties of the molecules, the “Drug-like properties” feature
allowing selection from 16 drug-likeness properties, and the “Reflinks” feature allowing
a search through various IDs from different databases. Links to PubChem, DrugBank,
PharmGKB, GenBank, Swiss-Prot, and KEGG database were provided which, in turn,
supports more specific information on taxanes.
Data extraction
The multi-tier relational database contains all the needed drug development informa-
tion on taxanes, which can be accessed through its two modes of search: the natural
taxane search and synthetic taxane search. Querying the TaxKB database is primarily
based on either “General Search” or specific “Parameter Specific Search” (Fig. 4) in the
“Search Taxanes’ section of the home page. The general search accepts queries led to
retrieve all the properties of particular taxanes in TaxKB. The user can view all the de-
tails of the selected taxane by using options such as “Taxane name,” “Drug-like
Fig. 3 Data flow and three level schema architecture of TaxKB
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used to access different properties of taxanes. It offers physicochemical properties,
drug-like properties, and Reflinks. The parameter-specific search consists of four fields.
In the first field, the user can choose any one particular taxane such as Paclitaxel or
Taxuspine. In the second field, physicochemical properties (e.g. molecular weight,
molecular formula, etc.) can be chosen. From the third field, drug-likeness properties
(e.g. H bond donor count, polar surface area, etc.) and similar modus operandi can be
applied to the fourth field, that is, “Reflinks” (e.g. PubChem ID and KEGG ID). The
user can select a particular property each from the respective field as their requirement
and execute the query that displays the desired information. Large availability of data
on semisynthetic taxanes makes their retrieval possible by using a simple property-
based specific-search. It includes different range of data on molecular weight, hydrogen
bond donor, hydrogen bond acceptor, LogP, and TPSA. This method depends upon
user’s search criteria with compounds that are retrieved based on either individual
property or group of properties.
Data analysis
The presented web-based TaxKB database is a new resource available for cancer drug
developers that would enable easy screening of clinically exploitable taxanes and allow
the generation of fragment and scaffold containing libraries and designing of novel
taxane leads with properties similar to the original compounds. Key features of the
database include the physicochemical and drug-likeness property data of taxanes of
both natural and synthetic origin.
Fig. 4 TaxKB Database organization showing the associated information included with each search option
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TaxKB is a single-information portal for the most successful blockbuster natural drug
compound ever discovered, namely, taxane. To our knowledge, it is the first and only
web-based resource integrating multidisciplinary data on taxanes as derived from
different drug development efforts so far. It provides a link between two independent
processes, taxane-based cancer drug development, and the ADME/T and thus provides
a better understanding and earlier detection of potential development failures. Hence,
it serves as an excellent online resource for taxane-related drug discovery. The motto
of today’s drug discovery and development industry is “Fail faster, Fail cheaper.” As a
result, scientists are constantly striving for new ways to eliminate poor drug candidates
earlier in the drug discovery cycle. The rapid pace of development of new and advanced
taxane analogs can enhance the overall quality of drugs and therefore health care.
TaxKB, as an information resource for taxanes, their analogs, and their properties can
assist researchers in developing new drug candidates based on the various properties of
these molecules. Several enhancements will be carried out in the upcoming release,
including incorporation of additional taxane structures as well as more properties of
these molecules, as new dimensions that can further improve the present pace of new
taxane drug discovery.
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